Wheeler, GM;
Mander, A;
Bedding, A;
Brock, K;
Cornelius, V;
Grieve, A;
Jaki, T;
... Bond, S; + view all
(2019)
How to design a dose-finding study using the Continual Reassessment Method.
BMC Medical Research Methodology
, 19
, Article 18. 10.1186/s12874-018-0638-z.
Preview |
Text
Wheeler VoR s12874-018-0638-z.pdf - Published Version Download (1MB) | Preview |
Abstract
The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to find the maximum tolerated dose (MTD) of a new therapy. The CRM has been shown to be more accurate in targeting the MTD than traditional rule-based approaches such as the 3 + 3 design, which is used in most phase I trials. Furthermore, the CRM has been shown to assign more trial participants at or close to the MTD than the 3 + 3 design. However, the CRM’s uptake in clinical research has been incredibly slow, putting trial participants, drug development and patients at risk. Barriers to increasing the use of the CRM have been identified, most notably a lack of knowledge amongst clinicians and statisticians on how to apply new designs in practice. No recent tutorial, guidelines, or recommendations for clinicians on conducting dose-finding studies using the CRM are available. Furthermore, practical resources to support clinicians considering the CRM for their trials are scarce.
| Type: | Article |
|---|---|
| Title: | How to design a dose-finding study using the Continual Reassessment Method |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s12874-018-0638-z |
| Publisher version: | https://doi.org/10.1186/s12874-018-0638-z |
| Language: | English |
| Additional information: | © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Keywords: | Adaptive designs, Continual reassessment method, Dose escalation, Dose-finding, Maximum tolerated dose, Phase I trials |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10064154 |
Archive Staff Only
 |
View Item |
